Fig. 3: FOXP4 is required for OV cells to maintain malignancy. | Cell Death & Disease

Fig. 3: FOXP4 is required for OV cells to maintain malignancy.

From: FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development

Fig. 3

A Real-time PCR was used to measure FOXP4 mRNA in A2780 cells transfected with pLKO or five specific FOXP4 shRNAs, n = 3. *p < 0.05 vs pLKO, **p < 0.01 vs pLKO, ***p < 0.001 vs pLKO. B The OV (A2780 and OVCAR8) cells stably expressing pLKO or two specific shRNAs against FOXP4 were subjected to immunoblotting with indicated antibodies. C The cell growth curve of A2780 and OVCAR8 cells in (B), n = 3. *p < 0.05 vs pLKO, **p < 0.01 vs pLKO. D Clonogenic assay of A2780 cells in (B), n = 3. *p < 0.05 vs pLKO, **p < 0.01 vs pLKO. E Caspase3/7 activity was measured in A2780 cells in (B). The y-axis indicates the Caspase3/7 activity over cell number. The value given for the caspase activity in control-infected cells was set as 100. F Incorporation of BrdU in A2780 cells in (B) was measured by ELISA, n = 3. **p < 0.01 vs pLKO. G Real-time PCR analysis of MKI67 mRNA in cells from (B), n = 3. ***p < 0.001 vs pLKO. H Migration rates of cells from (B) were evaluated, n = 3. **p < 0.01 vs pLKO, ***p < 0.001 vs pLKO. I A2780 cells stably expressing Con-shRNA or FOXP4-shRNA were inoculated subcutaneously in nude mice, respectively. Tumor volume was monitored over time, n = 6. **p < 0.01 vs Con-shRNA, ***p < 0.001 vs Con-shRNA. J Image representing the tumor on day 28, n = 6. K Bar graphs represent the weight of the tumor on day 28, n = 6. ***p < 0.001 vs Con-shRNA.

Back to article page